‘Is this genuine?’ JPMorgan court docket submitting reveals Frank workers questioned stats right before acquisition

‘Is this genuine?’ JPMorgan court docket submitting reveals Frank workers questioned stats right before acquisition


Important Factors
  • Staff members of a startup purchased by JPMorgan Chase expressed disbelief when the firm’s founder directed them to raise their buyer rely forward of the acquisition, according to internal messages introduced Thursday in a authorized submitting.
  • The founder, Charlie Javice, instructed personnel to improve “general public-experiencing figures” of university aid system Frank to 4.25 million prospects in January 2021, JPMorgan alleged in the filing.
  • “Do we definitely have 4.25M college students?” a single Frank staff questioned in a January 2021 Slack thread.



Supply

China didn’t grab many headlines at Davos, but it’s the elephant in the room
Finance

China didn’t grab many headlines at Davos, but it’s the elephant in the room

Davos 2026 China didn’t grab many headlines at Davos, but it’s the elephant in the room Published Sun, Jan 25 20267:04 PM ESTUpdated 56 Min Ago Evelyn Cheng@in/evelyn-cheng-53b23624@chengevelyn WATCH LIVE Source

Read More
Energy stocks to watch as major winter storm rips through the U.S.
Finance

Energy stocks to watch as major winter storm rips through the U.S.

Winter storm Fern is projected to have a wide-ranging impact on energy and power production. Here are a few stocks and energy related industry groups to watch around this and future storms. Natural gas producers The price move in natural gas has been profound. A 70% jump in the commodity in fewer than two weeks is stuff […]

Read More
Stocks making the biggest moves midday: Fortinet, Moderna, Intel, Bausch Health & more
Finance

Stocks making the biggest moves midday: Fortinet, Moderna, Intel, Bausch Health & more

Check out the companies making headlines in midday trading. Fortinet — Shares jumped more than 7% after TD Cowen upgraded the cybersecurity stock to buy from hold, saying rising memory prices won’t hurt the company as much as some suspect. The firm’s $100 price target suggests 29% upside ahead. Bausch Health — The pharmaceutical stock […]

Read More